Floatz logo

plx2853

Refractory Acute Myeloid Leukemia (AML)

Opna Bio LLCPhase 1Dormant
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
23/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Refractory Acute Myeloid Leukemia (AML) cohort.

Asset / SponsorPhaseRating
CD64 CAR T Cells
University of Colorado, Denver
Phase 1CC

Same molecule, other indications

plx2853 is also rated in:

uveal melanomaDormant
CC
Indicative ·
45 / 100
View asset →
myelodysplastic syndromeDormant
C
Indicative ·
38 / 100
View asset →
acute myeloid leukemiaDormant
C
Indicative ·
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →